Oramed Pharmaceuticals Inc (OJU1.SG)
| Previous close | 2.1390 |
| Open | 2.1610 |
| Bid | 2.1670 x 200000 |
| Ask | 2.2070 x 200000 |
| Day's range | 2.1610 - 2.2440 |
| 52-week range | 1.5930 - 4.2470 |
| Volume | |
| Avg. volume | 83 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireScilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the “Convertible Debentures”) previously issued and sold to YA II PN, Ltd. (“Yorkville”) in March 2023. Sci
Simply Wall St.Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Oramed Pharmaceuticals ( NASDAQ:ORMP ) Full Year 2023 Results Key Financial Results Net income: US$5.53m (up from...
PR NewswireOramed Letter to Shareholders
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.
